Navigation Links
AssureRx Appoints Senior Executives in Key Roles to Drive Company Growth
Date:2/1/2011

CINCINNATI, Feb. 1, 2011 /PRNewswire/ -- AssureRx Health, Inc. today announced the appointments of two senior executives in key roles to drive company growth. Donald R. Wright, Jr. has been appointed as executive vice president & chief operating officer and John A. Bellano as senior vice president, sales & commercial programs.

Wright has been instrumental in leading the development of AssureRx's pharmacogenetic test, GeneSightRx®, and the blueprint of products the company expects to develop over the next two to three years. In his new position, Wright will play a fundamental role in leading AssureRx's future product offerings, operations, and external relationships and he will continue managing software product development, overseeing information technology and molecular genetics laboratory operations, as well as customer support, field sales support, quality assurance, and human resources. Wright brings over 20 years of software product development and operations expertise, including Attachmate where he led a 700 member software team and the creation and support of a $450 million software product line. Wright also served as chief technology officer and chief information officer in various software companies and has participated in more than 25 successful product launches.

Bellano is joining AssureRx as a key member of the executive team, leading the company's sales efforts to increase adoption of GeneSightRx, launching new products in development, and leading the company's efforts with Diamond Healthcare and other strategic partners. Bellano also brings 20 years of experience to AssureRx, most recently as senior vice president, commercial operations for GenMark, a molecular diagnostics company, and as vice president, sales for Hologic Inc., a developer and manufacturer of women's health care products and systems. Prior to Hologic, Bellano served as vice president, sales for Third Wave, a provider of DNA and RNA products for the clinical and research markets, where he played a key role in building market adoption that led to Third Wave's acquisition by Hologic. Prior to Third Wave, John held various molecular diagnostic sales positions with Roche Diagnostics, Sanofi Diagnostics Pasteur, Abbott Laboratories and Forest Laboratories.

"Our goal is to build the leading medical informatics company providing pharmacogenetic and other clinical decision support products to help physicians individualize the treatment of patients with neuropsychiatric and other disorders," said James S. Burns, president & CEO of AssureRx. "Strengthening the leadership team is an important step for AssureRx this year as we build sales momentum and launch our second product. Don and John have the leadership skills and experience to meet our customers' needs for treatment support products that can help improve patient care at substantially reduced costs."

About AssureRx HealthAssureRx Health, Inc. is a personalized medicine company that specializes in pharmacogenetics and other treatment decision support products to help physicians determine the right drug and the right dose for individual patients suffering from neuropsychiatric disorders. The company was founded in 2006 to commercialize industry-leading personalized medicine technology. Cincinnati Children's Hospital Medical Center and Mayo Clinic are equity holders and technology collaborators.

About GeneSightRx®

GeneSightRx® is a laboratory developed genetic test that uses leading edge technology to measure and analyze clinically important genetic variants that affect how individuals metabolize psychiatric medicine. The test results can help a doctor understand the way a patient's unique genetic makeup may affect certain psychiatric drugs. The analysis is based on pharmacogenetics, the study of the genetic factors that influence an individual's response to drug treatments, incorporating FDA approved manufacturers' drug labels, peer-reviewed scientific publications, and proven pharmacology. Quick turnaround time, combined with a customized report of the patient's genetic makeup, clinical experience, and other factors can help a physician make personalized drug treatment choices for each individual patient. To learn more about pharmacogenetics and GeneSightRx, please click here. Be sure to watch the educational video.Contacts:James S. BurnsPresident & CEOAssureRx Health, Inc.Tel: (513) 234-0510e-mail: jburns@assurerxhealth.comAndreas Marathovouniotis or David Schull Russo PartnersTel: (212) 845-4235 or (212) 845-4271e-mail: andreas.marathis@russopartnersllc.com or david.schull@russopartnersllc.com
'/>"/>

SOURCE AssureRx Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hologic Appoints Mark D. Myslinski as Senior Vice President and General Manager of Diagnostics
2. Sysmex America Appoints Vice President of Sales
3. PDL BioPharma Appoints Caroline Krumel as Vice President of Finance and Thanks Karen Wilson for her Contributions
4. NxStage® Appoints Nancy J. Ham to Its Board of Directors and Announces Resignation of Board Member Jonathan T. Silverstein
5. WaferGen Appoints World-Renowned Clinical Genomics Cancer Researcher Dr. Arul M. Chinnaiyan to Scientific Advisory Board
6. Interventional Spine®, Inc. Appoints Stephen Colaiezzi, Senior Vice President, Strategic Marketing
7. Solta Medical, Inc. Appoints Thomas J. Yorkey, Ph.D. to Vice President of Research & Development
8. Symmetry Medical Board of Directors Appoints Thomas J. Sullivan President and Chief Executive Officer
9. Optimer Pharmaceuticals Appoints Hank McKinnell to Its Board of Directors
10. Karyopharm Therapeutics Inc. Appoints Michael Kauffman, MD, PhD, as Chief Executive Officer
11. Cephalon Appoints J. Kevin Buchi as Chief Executive Officer and Member of Cephalon Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... 2016  Results from the Phase II SUSTAIN study ... reduced the median annual rate of sickle cell-related pain ... 2.98, p=0.010) in patients with or without hydroxyurea therapy ... being featured in the official press briefing at the ... Meeting and presented during the Plenary Scientific Session tomorrow ...
(Date:12/2/2016)... December 2, 2016 - bioLytical lanza el INSTI HIV ... la OMS     Continue Reading ... ... , , bioLytical ... anunciado hoy que está expandiendo el lanzamiento de su INSTI HIV Self Test ...
(Date:12/2/2016)... December 2, 2016 According to the ... Market Study on Automated Endoscope Reprocessors: Single Basin Automated Endoscope ... 8.6% Between 2016 and 2024 " the global automated endoscope reprocessors market was ... to expand at a CAGR of 7.2% during an eight-year ... 1,367.6 Mn by 2024. ...
Breaking Medicine Technology:
(Date:12/4/2016)... , ... December 03, 2016 , ... While James Earl ... serving as host for in a show called "Front Page". One of the forthcoming ... years, breast cancer rates have plummeted in large part due to early detection. Like ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients who wish to ... advantage of a cosmetic procedure known as Carbon Dioxide (C02) Fractional Laser ... of age spots, fine lines, uneven coloration, wrinkles, scarring, skin laxity or ...
(Date:12/2/2016)... ... December 02, 2016 , ... Lori G. Cohen and ... will speak at the American Conference Institute’s 21st Drug & Medical Device Litigation ... Lead Sponsor of the conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device ...
(Date:12/2/2016)... ... December 02, 2016 , ... More than 100 business, civic, ... to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon Dec. 9, 2016. This inaugural event, ... and operating support to UNCF-member institutions, including Miles College, Oakwood University, Tuskegee University, ...
(Date:12/2/2016)... ... , ... The annual time frame to change Medicare health and prescription drug ... 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to ... make changes during this period order for their new policy to go into effect ...
Breaking Medicine News(10 mins):